Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF — Stella

Recruiting

Back to Transthyretin Amyloidosis trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

United States

Massachusetts General Hospital, Boston, Massachusetts

Key details

Sponsor

Massachusetts General Hospital

Collaborators

Akcea Therapeutics, Pfizer

Enrollment target

~515 participants

Started

October 2020

Primary completion

June 2026

Age range

65 Years and older

Last updated December 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov